• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Serum cystatin C as a new marker for determining the optimal dosage of renally excreted drugs.

Research Project

Project/Area Number 15590138
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeSingle-year Grants
Section一般
Research Field Medical pharmacy
Research InstitutionKeio University

Principal Investigator

MORITA Kunihiko  Keio university, department of medicine, Associate Professor, 医学部, 助教授 (80327717)

Co-Investigator(Kenkyū-buntansha) TANIGAWA Yusuke  Keio University, Department of Medicine, Professor, 医学部, 教授 (30179832)
ASANO Koichiro  Keio University, Department of Medicine, Assistant Professor (60192944)
山口 佳寿博  慶應義塾大学, 医学部, 助教授 (30129712)
Project Period (FY) 2003 – 2004
Project Status Completed (Fiscal Year 2004)
Budget Amount *help
¥3,600,000 (Direct Cost: ¥3,600,000)
Fiscal Year 2004: ¥1,000,000 (Direct Cost: ¥1,000,000)
Fiscal Year 2003: ¥2,600,000 (Direct Cost: ¥2,600,000)
Keywordscvstatin C / creatinin clearance / vancomycin / teicoplanin / carboplatin / renally excreted drug / determining dosage / dosage adjustment / 血清クレアチニン / メトトレキサート / 血清尿素窒素 / 腎機能 / 薬物血中濃度モニタリング / バンコマイシン
Research Abstract

Cystatin C(Cys C), a new endogenous marker of renal function, is believed to be superior to serum creatinine(Scr) or calculated creatinine clearance(Ccr) as an indicator of renal function. Although serum Cys C is one of the most predominant candidates in the estimation of renal function, there are few reports applying serum Cys C to the dosage adjustment of renally excreted drugs such as vancomycin(VCM), teicoplanin(TEIC) and carboplatin. We compared retrospectively the usefulness of cystatin C with that of Ccr in the prediction of total clearance(CLtot) of VCM, TEIC and carboplatin, in advance of the investigation whether serum Cys C concentration is a better marker in the prediction of dosing regimen than calculated Ccr. Age, body weight(BW), 5cr, BUN, Ccr, and Cys C is distributed widely. Good correlation was shown between 5cr and Cys C. Calculated Ccr also correlated significantly with 1/Cys C. Both 1/Cys C adjusted by BW and calculated Ccr correlated significantly with TEIC CLtot. Our results clearly demonstrated that CLtot of VCM and TEIC correlated well with 1/Cys C adjusted by BW. Furthermore, the correlation coefficients in the case of 1/Cys C adjusted by BW were higher than those in the case of the Ccr calculated by the Cockcroft-Gault formula. The results in this study enable us to predict the CLtot of VCM and TEIC using the regression equation as shown below. The similar results were obtained in carboplatin CL. Patients with abnormally low Scr, fluctuated Scr, and severe infection, and elderly patients may have a benefit when accurate estimate of the CLtot is quickly needed for the determination of optimal dosage regimen. Furthermore, Cys C is expected to be clinically useful to estimate CLtot of the other drugs excreted mainly by the kidney. Our study suggested effective strategy to optimize dosage regimen of those agents.

Report

(3 results)
  • 2004 Annual Research Report   Final Research Report Summary
  • 2003 Annual Research Report
  • Research Products

    (10 results)

All 2005 2004 2003 Other

All Journal Article (9 results) Publications (1 results)

  • [Journal Article] Serum cystatin C as a new marker for determining the optimal dosage of renally excreted drugs.2005

    • Author(s)
      O.Iketani, K.Morita et al.
    • Journal Title

      The Keio Journal of Medicine 54

      Pages: 39-39

    • NAID

      10015422632

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      2004 Final Research Report Summary
  • [Journal Article] 抗菌薬のPK/PDと透析患者への適正投与法2005

    • Author(s)
      森田邦彦
    • Journal Title

      透析会誌 38

      Pages: 97-98

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      2004 Annual Research Report 2004 Final Research Report Summary
  • [Journal Article] Serum cystatin C as a new marker for determining the optimal dosage of renally wxcreted drugs.2005

    • Author(s)
      Iketani O, Morita K et al.
    • Journal Title

      The Keio Journal of Medicine 54

      Pages: 39-39

    • Related Report
      2004 Annual Research Report
  • [Journal Article] Vitreous concentrations of triamcinolone acetonide in human eyes after intravitreal or subtenon injection.2004

    • Author(s)
      Inoue M, Morita K et al.
    • Journal Title

      Am J Ophthalmol. 138

      Pages: 1046-1048

    • Related Report
      2004 Annual Research Report
  • [Journal Article] PK/PDからみた抗菌薬適正使用の実際2004

    • Author(s)
      森田邦彦
    • Journal Title

      月刊薬事 46(12)

      Pages: 2157-2163

    • Related Report
      2004 Annual Research Report
  • [Journal Article] 新しい腎機能マーカー・血清シスタチンC濃度を用いた腎排泄型薬物投与設計の有用性2003

    • Author(s)
      池谷修, 森田邦彦ほか
    • Journal Title

      臨床薬理 34

    • NAID

      10011422193

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      2004 Final Research Report Summary
  • [Journal Article] カルバペネム系抗生物質・メロペネムの血中濃度と臨床効果との関係解析2003

    • Author(s)
      森田邦彦ほか
    • Journal Title

      TDM研究 20

      Pages: 189-190

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      2004 Final Research Report Summary
  • [Journal Article] Depression of phenytoin metabolic capacity by 5-fluorouracil and doxifluridine in rats2003

    • Author(s)
      H.Konishi, K.Morita et al.
    • Journal Title

      J.Pharm.Pharmacol. 55

      Pages: 143-149

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      2004 Final Research Report Summary
  • [Journal Article] Depression of phenytoin metabolic capacity by 5-fluorouradil and doxifluridine in rats2003

    • Author(s)
      H.Konishi, K.Morita et al.
    • Journal Title

      J.Pharm.Pharmacol. 55

      Pages: 143-149

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      2004 Final Research Report Summary
  • [Publications] H.Konishi, et al.: "Depression of phenytoin metabolic capacity by 5-fluorouracil and doxifluridine in rats."J.Pharm.Pharmacol.. 55. 143-149 (2003)

    • Related Report
      2003 Annual Research Report

URL: 

Published: 2003-04-01   Modified: 2016-04-21  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi